Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

  • BioNTech diversified into cancer treatments, FY 2025 revenue grew to $3.2 billion (+4.3% YoY)
  • Moderna faced 40% YoY revenue decline in 2025, net loss of $2.8 billion
  • BioNTech has $16.2B cash reserves, Moderna has $8B, Moderna's revenue grew 29% in Q3 2026

More from Monday 9 November →